Intracoronary abciximab use in patients undergoing PCI at a community hospital: a single operator experience.
Publication/Presentation Date
6-1-2008
Abstract
OBJECTIVE: To evaluate the safety of intracoronary (IC) abciximab during percutaneous coronary intervention (PCI).
BACKGROUND: Adjunctive treatment with glycoprotein IIb/IIIa inhibitors, especially abciximab, during PCI has been shown to improve clinical and procedural outcomes in numerous studies. However, significant bleeding complications exist with its use and this has limited its standard use. Interest has grown in local (IC) use with studies showing safety and long-term effectiveness, especially in patients with high thrombus loads.
METHODS: A retrospective review of records in a database of patients who had PCI by a single operator at the Easton Hospital.
RESULTS: 611 patients received IC abciximab, and there were no complications in 610 (98.3%) patients; only 1 had an allergic reaction.
CONCLUSIONS: IC abciximab is safe and has a unique role in the catheterization lab and in patients at high risk of bleeding complications who would benefit from its limited use.
Volume
13
Issue
2
First Page
89
Last Page
93
ISSN
1074-2484
Published In/Presented At
Patel, S. S., Rana, H., & Mascarenhas, D. A. (2008). Intracoronary abciximab use in patients undergoing PCI at a community hospital: a single operator experience. Journal of cardiovascular pharmacology and therapeutics, 13(2), 89–93. https://doi.org/10.1177/1074248408316485
Disciplines
Medicine and Health Sciences
PubMedID
18413897
Department(s)
Department of Medicine
Document Type
Article